Kengo Azushima

ORCID: 0000-0002-5136-0730
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Renin-Angiotensin System Studies
  • Hormonal Regulation and Hypertension
  • Blood Pressure and Hypertension Studies
  • Chronic Kidney Disease and Diabetes
  • Diabetes Treatment and Management
  • Receptor Mechanisms and Signaling
  • Adipose Tissue and Metabolism
  • Adipokines, Inflammation, and Metabolic Diseases
  • Sodium Intake and Health
  • Potassium and Related Disorders
  • Heart Rate Variability and Autonomic Control
  • Dialysis and Renal Disease Management
  • Ion Transport and Channel Regulation
  • Heart Failure Treatment and Management
  • Cardiovascular Health and Disease Prevention
  • COVID-19 Clinical Research Studies
  • Lipoproteins and Cardiovascular Health
  • Pancreatic function and diabetes
  • Nephrotoxicity and Medicinal Plants
  • Renal Diseases and Glomerulopathies
  • Apelin-related biomedical research
  • SARS-CoV-2 and COVID-19 Research
  • Diet and metabolism studies
  • Iron Metabolism and Disorders
  • Pharmacology and Obesity Treatment

Yokohama City University
2016-2025

Duke-NUS Medical School
2017-2023

Japan Society for the Promotion of Science
2023

National University of Singapore
2020

Kumamoto University
2013

Tokyo Medical and Dental University
2013

Tulane University
2013

Abstract Tumor necrosis factor (TNF)-α is a potent mediator of inflammation and involved in the pathophysiology chronic kidney disease (CKD). However, effects TNF-α inhibition on progression fibrosis have not been fully elucidated. We examined by etanercept (ETN) mice with aristolochic acid (AA) nephropathy as model fibrosis. C57BL/6 J were administered AA for 4 weeks, followed 4-week remodeling period. The exhibited fibrosis, functional decline, albuminuria concomitant increases renal mRNA...

10.1038/s41598-021-02864-1 article EN cc-by Scientific Reports 2021-12-08

Activation of tissue angiotensin II (Ang II) type 1 receptor (AT1R) plays an important role in the development vascular remodelling. We have shown that AT1R-associated protein (ATRAP/Agtrap), a specific binding AT1R, functions as endogenous inhibitor to prevent pathological activation renin-angiotensin system. In this study, we investigated effects ATRAP on Ang II-induced remodelling.Transgenic (Tg) mice with pattern aortic vascular-dominant overexpression were obtained, and or vehicle was...

10.1093/cvr/cvt225 article EN Cardiovascular Research 2013-11-04

Angiotensin II type 1 receptor (AT1R)–associated protein (ATRAP) promotes AT1R internalization along with suppression of pathological activation tissue signaling. However, the functional significance ATRAP in renal sodium handling and blood pressure regulation under stimuli is not fully resolved. Here we show mice a gene-targeted disruption was comparable to that wild-type at baseline. ATRAP-knockout mice, angiotensin II–induced hypertension exacerbated extent positive balance increased by...

10.1038/ki.2014.95 article EN cc-by-nc-nd Kidney International 2014-04-02

Diabetic nephropathy (DN) is a leading cause of end-stage renal disease worldwide, but its molecular pathogenesis not well defined, and there are no specific treatments. In humans, strong genetic component determining susceptibility to DN. However, genes controlling DN in humans have been identified. this study, we describe mouse model combining type 1 diabetes with activation the renin-angiotensin system (RAS), which develops robust kidney features resembling human DN: heavy albuminuria,...

10.2337/db17-1323 article EN Diabetes 2018-07-31

Ischemia reperfusion injury (IRI) is a major cause of acute kidney (AKI) and ultimately leads to renal fibrosis, primarily via the transforming growth factor-β (TGF-β) pathway. Leucine-rich alpha-2-glycoprotein 1 (LRG1), novel modulator TGF-β pathway, has been implicated in modulation fibrosis by affecting TGF-β/Smad3 signaling axis. However, role LRG1 transition from AKI chronic disease (CKD) remains unclear. This study aimed investigate functional during remodeling phase post-IRI....

10.1038/s41598-024-84798-y article EN cc-by-nc-nd Scientific Reports 2025-01-08

Abstract Background We investigated the effects of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), on 24-hour blood pressure (BP) and safety for 12 weeks in Japanese patients with non-dialysis advanced chronic kidney disease (CKD). Methods conducted prospective, single-arm exploratory study. Patients CKD stage G4-5 (estimated glomerular filtration (eGFR) <30 mL/min/1.73 m2) who did not achieve their BP goals blocker (ARB) administration, were...

10.1093/ajh/hpaf028 article EN American Journal of Hypertension 2025-03-10

We have previously shown that angiotensin II type 1 receptor-associated protein (ATRAP/ Agtrap ) interacts with the receptor and promotes constitutive internalization of so as to inhibit pathological activation its downstream signaling but preserve baseline physiological activity. The present study was designed investigate role renal ATRAP in II–dependent hypertension. generated transgenic mice dominantly expressing tubules, including distal tubules. exhibited no significant change blood...

10.1161/hypertensionaha.111.00572 article EN Hypertension 2013-03-26

Background Metabolic disorders with visceral obesity have become a major medical problem associated the development of hypertension, type 2 diabetes, and dyslipidemia and, ultimately, life‐threatening cardiovascular renal diseases. Adipose tissue dysfunction has been proposed as cause obesity‐related metabolic disorders, moving toward proinflammatory phenotype. Methods Results Here we first report that adipose tissues from patients mice exhibit decreased expression ATRAP / Agtrap , which is...

10.1161/jaha.113.000312 article EN cc-by-nc-nd Journal of the American Heart Association 2013-08-01

The renin-angiotensin system has a pivotal role in the pathophysiology of visceral obesity. Angiotensin II type 1 receptor (AT1R) is major player signal transduction system, and overactivation this signaling contributes to progression We have shown that AT1R-associated protein (ATRAP) promotes AT1R internalization from cell surface into cytoplasm along with suppression tissue signaling. In study, we examined whether enhancement adipose ATRAP expression could efficiently prevent diet-induced...

10.1161/jaha.116.004488 article EN cc-by-nc-nd Journal of the American Heart Association 2017-03-01

Abstract Background The Y-AIDA study was designed to investigate the renal- and home blood pressure (BP)-modulating effects of add-on dapagliflozin treatment in Japanese individuals with type 2 diabetes mellitus (T2DM) albuminuria. Methods We conducted a prospective, multicenter, single-arm study. Eighty-six patients T2DM, HbA1c 7.0–10.0%, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m , urine albumin-to-creatinine ratio (UACR) 30 mg/g creatinine (gCr) were enrolled, 85 these...

10.1186/s12933-019-0912-3 article EN cc-by Cardiovascular Diabetology 2019-08-27

The kidney is one of the most susceptible organs to age-related impairments. Generally, renal aging accompanied by fibrosis, which final common pathway chronic diseases. Aristolochic acid (AA), a nephrotoxic agent, causes AA nephropathy (AAN), characterized progressive fibrosis and functional decline. Although associated with aging, whether induces remains unclear. aim present study investigate potential use AAN as model aging. Here, we examined senescence-related factors in models...

10.3390/ijms222212432 article EN International Journal of Molecular Sciences 2021-11-18

To compare the therapeutic effects of glucose-dependent insulinotropic polypeptide (GIP)/ glucagon-like peptide-1 receptor agonists (GLP-1RAs) or GLP-1RAs in Japanese patients with type 2 diabetes (T2D).We systematically searched PubMed, MEDLINE, EMBASE, and Cochrane Library up to July 2023. Randomized controlled trials (RCTs) that compared GIP/GLP-1RAs T2D were selected. A network meta-analysis was conducted indirectly treatments, focusing on efficacy reducing glycated haemoglobin (HbA1c)...

10.1111/dom.15312 article EN Diabetes Obesity and Metabolism 2023-10-12
Coming Soon ...